Overview

Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Anagrelide